Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients
Biomarker-based post-transplant immune monitoring for the prediction of impending graft rejection requires validation in specific patient populations. Serum of 28 pediatric renal transplant recipients within the framework of a well-controlled prospective randomized trial was analyzed pre- and post-t...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Transplant international
Year: 2013, Volume: 26, Issue: 3, Pages: 331-338 |
| ISSN: | 1432-2277 |
| DOI: | 10.1111/tri.12049 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1111/tri.12049 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/tri.12049 
|
| Author Notes: | Heiko Billing, Anja Sander, Caner Süsal, Jörg Ovens, Reinhard Feneberg, Britta Höcker, Karel Vondrak, Ryszard Grenda, Stybjorn Friman, David V. Milford, Mihai Lucan, Gerhard Opelz and Burkhard Tönshoff |
| Summary: | Biomarker-based post-transplant immune monitoring for the prediction of impending graft rejection requires validation in specific patient populations. Serum of 28 pediatric renal transplant recipients within the framework of a well-controlled prospective randomized trial was analyzed pre- and post-transplant for soluble CD30 (sCD30), a biomarker reflecting mainly T-cell reactivity, and anti-human leukocyte antigen (anti-HLA) antibody reactivity, a biomarker for B-cell activation. A sCD30 concentration ≥40.3 U/ml on day 14 was able to discriminate between patients with or without biopsy-proven acute rejection (BPAR) with a sensitivity of 100% and a specificity of 76%. Six of seven patients (86%) with BPAR showed a sCD30 above this cut-off, whereas only 3/21 patients (14%) without BPAR had a sCD30 above this cut-off (P = 0.004). For pre- and post-transplant anti-HLA class II reactivities by enzyme-linked immunosorbent assay, a cut-off value of 140 optical density was able to discriminate rejecters from nonrejecters with a sensitivity of 86% or 71% and a specificity of 81% or 90%, respectively. Withdrawal of steroids was associated with a approximately twofold higher serum sCD30 compared to controls, but did not affect anti-HLA reactivities. An increased post-transplant sCD30 serum concentration and positive pre- and post-transplant anti-HLA class II reactivities are informative biomarkers for impending BPAR in pediatric renal transplant recipients. (TWIST, Clinical Trial No: FG-506-02-43) |
|---|---|
| Item Description: | Gesehen am 26.07.2018 Published online: 31 December 2012 |
| Physical Description: | Online Resource |
| ISSN: | 1432-2277 |
| DOI: | 10.1111/tri.12049 |